PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2017 August; 61(8): e00638-17.
Published online 2017 July 25. Prepublished online 2017 May 30. doi:  10.1128/AAC.00638-17
PMCID: PMC5527614

Simkania negevensis, an Example of the Diversity of the Antimicrobial Susceptibility Pattern among Chlamydiales

ABSTRACT

In past years, several Chlamydia-related bacteria have been discovered, including Simkania negevensis, the founding member of the Simkaniaceae family. We evaluated the antimicrobial susceptibility patterns of this emerging intracellular bacterium and highlighted significant differences, compared with related Chlamydiales members. S. negevensis was susceptible to macrolides, clindamycin, cyclines, rifampin, and quinolones. Importantly, unlike other Chlamydiales members, treatment with β-lactams and vancomycin did not induce the formation of aberrant bodies, leading to a completely resistant phenotype.

KEYWORDS: Chlamydiales, Simkaniaceae, intracellular bacteria

TEXT

Rapid progress in diagnostic techniques has enabled the discovery of several novel Chlamydia-related bacteria, including Simkania negevensis. Mostly known for the pathogenic Chlamydia spp., the Chlamydiales order is now composed of at least 9 family-level lineages (1), each with specific biological characteristics. S. negevensis is the founding member of the Simkaniaceae family and represents an emerging pathogen previously associated with respiratory diseases, at least in the Middle East (2, 3). Infections were empirically treated with a macrolide-based regimen (4). Several differences regarding antimicrobial susceptibility have been highlighted among the different Chlamydiales family-level lineages (5, 6). Therefore, we investigated the antibiotic susceptibility of the Simkaniaceae family, which remains poorly studied, using S. negevensis as a model. We provide subsequent information on the evolution of antimicrobial resistance in this order, as well as potential therapeutic options.

Simkania negevensis strain Z was grown at 37°C in Vero cells in 25-cm2 cell culture flasks (Corning, USA), in Dulbecco's modified essential medium (DMEM) (PAN Biotech, Aidenbach, Germany) supplemented with 10% fetal calf serum (FCS), with 5% CO2. A 6- or 7-day-old coculture, diluted 1:1,000, was used to inoculate fresh A549 cells or Vero cells that had been seeded previously at 1.5 × 105 cells/ml on a 24-well plate (Corning), as described previously (7). At 2 h postinfection, the medium was changed for medium containing 2-fold serial dilutions of various antibiotics. Antibiotic-free wells served as growth controls, while uninfected cells served as negative controls. Twelve antibiotics from 8 different classes were used in this study. MICs were defined as the minimal concentrations that prevented bacterial growth at day 6, compared to a control infection performed in the absence of antibiotics. Growth at day 2 was also assessed for β-lactams, fosfomycin, and vancomycin, to ensure the absence of effects due to instability of the compounds after 48 h at 37°C. An in-house specific quantitative PCR targeting the 16S rRNA gene was used to quantify S. negevensis DNA, as described previously (7). The absence of antibiotic toxicity toward cells was determined by examining the microplates using an inverted microscope (Zeiss Axiovert 25; Carl Zeiss). When solvents other than distilled water (i.e., dimethyl sulfoxide [DMSO], 0.1 M HCl, and 1 M NaOH) were used to suspend antibiotic solutions, the absence of effects of these solvents on S. negevensis growth was assessed.

Like other Chlamydiales species, S. negevensis was susceptible to macrolides, clindamycin, cyclines, and rifampin (Table 1). Interestingly, S. negevensis was susceptible to quinolones; while Chlamydiaceae are sensitive, other Chlamydia-related bacteria, such as Waddlia chondrophila, Parachlamydia spp., and Estrella lausannensis, are resistant (5, 6, 8). Previous work suggested that S. negevensis was resistant to ciprofloxacin (9). In that study, MICs were determined in amoebae, as the minimal concentrations that prevented amoebal lysis. The observed results might have been due to the presence of an efflux pump in amoebae and decreasing quinolone bioavailability. Although several mutations in the gyrA and parC quinolone resistance-determining regions (QRDRs) were identified, they differed from those observed in resistant Chlamydia-related bacteria, which may explain the observed absence of resistance (6, 9).

TABLE 1
Antibiotic susceptibility of Simkania negevensis, compared to others Chlamydialesa

S. negevensis was resistant (MICs of >32 μg/ml) to three kinds of cell wall inhibitors, i.e., β-lactams, fosfomycin, and vancomycin. Chlamydiales members lack the traditional peptidoglycan (PG) layer. However, partial susceptibility to β-lactams is observed among Chlamydia spp., which are known to form aberrant bodies when treated with penicillin derivatives (10), while W. chondrophila is susceptible to high doses of fosfomycin (11). Aberrant bodies represent enlarged forms of the bacterium, due to abnormal division despite persisting DNA replication (11). Therefore, we evaluated the morphology of S. negevensis particles treated with β-lactams, fosfomycin, and vancomycin, in immunofluorescence assays using an in-house rabbit polyclonal anti-S. negevensis antibody, as described previously (7). As shown in Fig. 1A, no abnormal morphological aspects of S. negevensis could be observed with β-lactam treatment, even with concentrations as high as 1,000 μg/ml. This contrasted strikingly with the abnormal morphology of Chlamydia trachomatis observed with 2 μg/ml β-lactams, making S. negevensis unique among Chlamydiales members. Indeed, W. chondrophila (in the Waddliaceae family) and E. lausannensis (in the Criblamydiaceae family) form aberrant bodies with β-lactam treatment (500 μg/ml) (6, 12). Furthermore, unlike W. chondrophila (11), S. negevensis replication was not inhibited by high doses of β-lactams (1,000 μg/ml) (Table 1). This difference could not be explained by the slower replicative cycle, as similar observations were made at day 6 postinfection (Fig. 1B). Several β-lactamase motifs are included in the S. negevensis genome (13) and may contribute to the phenotype. However, W. chondrophila exhibits partial sensitivity to high doses of β-lactams despite having a class C β-lactamase encoded in its genome (14).

FIG 1
Effects of cell wall inhibitors on Simkania negevensis infection and morphology. The growth of S. negevensis was observed by immunofluorescence, in the presence or absence of cell wall inhibitors. (A) Effects of β-lactam, fosfomycin, and vancomycin ...

Similarly to Chlamydia spp. (11), S. negevensis replication was not inhibited by high doses of fosfomycin, which targets the enzyme MurA (implicated in the early steps of PG biosynthesis). However, a small fraction of S. negevensis particles, which increased by day 6, showed abnormal morphological features consistent with aberrant bodies (Fig. 1A and andB),B), although remaining significantly less important than observed for W. chondrophila (11). Chlamydia resistance to fosfomycin is suspected to be related to a single substitution (Cys115 to Asp) in the active site of MurA (11, 15). This mutation was not found in S. negevensis, supporting the observed partially sensitive phenotype. Finally, we did not observe aberrant bodies with vancomycin treatment, a drug that inhibits transpeptidation through high-affinity binding to the d-alanine precursor (Fig. 1A).

Recently, several works have demonstrated the presence of a modified version of PG, which is required for cell division (12, 16, 17), in Chlamydiales members, thus explaining their partial sensitivity to cell wall inhibitors. Interestingly, a recent study failed to isolate PG-like structures in S. negevensis (18), while such structures were identified in Protochlamydia amoebophila (18) and C. trachomatis (17). In the same work, incorporation of fluorescently labeled d-alanine could not be highlighted in S. negevensis (18), which correlates with the absence of vancomycin effects observed here. However, a previous work showed that, similarly to C. trachomatis, S. negevensis was susceptible to d-cycloserine, a molecule that inhibits the alanine racemase Alr and the alanine ligase Ddl, which are required for d-alanine formation (19). While a predicted Ddl enzyme is encoded in the S. negevensis genome, no Alr coding sequence is present, similarly to Chlamydiaceae (12). It is not known whether the serine hydroxymethyltransferase GlyA encoded in the S. negevensis genome could compensate for the absence of Alr, as described for Chlamydiaceae (20).

Despite the absence of PG-like structures, the activity of two PG-remodeling enzymes, NlpD and AmiA, was documented in S. negevensis (16), and enzymes implicated in PG biosynthesis are highly conserved among Chlamydiales members, including S. negevensis, which supports their crucial role (12). However, the different responses to different cell wall inhibitors, each targeting a specific step of PG biosynthesis, indicate that, despite the likely requirement for a modified form of PG for cell division, some significant differences exist in the PG biosynthesis pathway of S. negevensis, which might bring further insights into the mechanisms of Chlamydiales cell division.

In conclusion, in this work we highlighted several differences in the antimicrobial responses of S. negevensis, compared to other Chlamydiales members. Although the pathogenic role of Simkania spp. remains to be better defined, the precise knowledge of their antimicrobial susceptibility patterns provides significant information regarding the biology and evolution of the Chlamydiales order.

ACKNOWLEDGMENTS

This work was supported by the Swiss National Science Foundation (SNSF) (MD-PhD grant 323530-158123 and grant 310030-162603).

We do not report any potential conflicts of interest.

REFERENCES

1. Pillonel T, Bertelli C, Salamin N, Greub G 2015. Taxogenomics of the Chlamydiales. Int J Syst Evol Microbiol 65:1381–1393. doi:.10.1099/ijs.0.000090 [PubMed] [Cross Ref]
2. Al-Younes HM, Paldanius M 2014. High seroprevalence of Simkania negevensis in Jordan. Braz J Microbiol 45:1433–1437. doi:.10.1590/S1517-83822014000400038 [PMC free article] [PubMed] [Cross Ref]
3. Kahane S, Greenberg D, Friedman MG, Haikin H, Dagan R 1998. High prevalence of “Simkania Z,” a novel Chlamydia-like bacterium, in infants with acute bronchiolitis. J Infect Dis 177:1425–1429. doi:.10.1086/517830 [PubMed] [Cross Ref]
4. Lieberman D, Kahane S, Lieberman D, Friedman MG 1997. Pneumonia with serological evidence of acute infection with the Chlamydia-like microorganism “Z”. Am J Respir Crit Care Med 156:578–582. doi:.10.1164/ajrccm.156.2.9608081 [PubMed] [Cross Ref]
5. Goy G, Greub G 2009. Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae. Antimicrob Agents Chemother 53:2663–2666. doi:.10.1128/AAC.00046-09 [PMC free article] [PubMed] [Cross Ref]
6. de Barsy M, Bottinelli L, Greub G 2014. Antibiotic susceptibility of Estrella lausannensis, a potential emerging pathogen. Microbes Infect 16:746–754. doi:.10.1016/j.micinf.2014.08.003 [PubMed] [Cross Ref]
7. Vouga M, Baud D, Greub G 2017. Simkania negevensis may produce long-lasting infections in human pneumocytes and endometrial cells. Pathog Dis 75:ftw115. doi:.10.1093/femspd/ftw115 [PMC free article] [PubMed] [Cross Ref]
8. Vouga M, Diabi H, Boulos A, Baud D, Raoult D, Greub G 2015. Antibiotic susceptibility of Neochlamydia hartmanellae and Parachlamydia acanthamoebae in amoebae. Microbes Infect 17:761–765. doi:.10.1016/j.micinf.2015.08.002 [PubMed] [Cross Ref]
9. Casson N, Greub G 2006. Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes. Int J Antimicrob Agents 27:541–544. doi:.10.1016/j.ijantimicag.2006.03.009 [PubMed] [Cross Ref]
10. Hammerschlag MR, Gleyzer A 1983. In vitro activity of a group of broad-spectrum cephalosporins and other beta-lactam antibiotics against Chlamydia trachomatis. Antimicrob Agents Chemother 23:493–494. doi:.10.1128/AAC.23.3.493 [PMC free article] [PubMed] [Cross Ref]
11. Jacquier N, Frandi A, Pillonel T, Viollier P, Greub G 2014. Cell wall precursors are required to organize the chlamydial division septum. Nat Commun 5:3578. doi:.10.1038/ncomms4578 [PMC free article] [PubMed] [Cross Ref]
12. Jacquier N, Viollier P, Greub G 2015. The role of peptidoglycan in chlamydial cell division: towards resolving the chlamydial anomaly. FEMS Microbiol Rev 39:262–275. doi:.10.1093/femsre/fuv001 [PubMed] [Cross Ref]
13. Collingro A, Tischler P, Weinmaier T, Penz T, Heinz E, Brunham RC, Read TD, Bavoil PM, Sachse K, Kahane S, Friedman MG, Rattei T, Myers GSA, Horn M 2011. Unity in variety: the pan-genome of the Chlamydiae. Mol Biol Evol 28:3253–3270. doi:.10.1093/molbev/msr161 [PMC free article] [PubMed] [Cross Ref]
14. Bertelli C, Collyn F, Croxatto A, Rückert C, Polkinghorne A, Kebbi-Beghdadi C, Goesmann A, Vaughan L, Greub G 2010. The Waddlia genome: a window into chlamydial biology. PLoS One 5:e10890. doi:.10.1371/journal.pone.0010890 [PMC free article] [PubMed] [Cross Ref]
15. Nagai K, Davies TA, Jacobs MR, Appelbaum PC 2002. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 46:1273–1280. doi:.10.1128/AAC.46.5.1273-1280.2002 [PMC free article] [PubMed] [Cross Ref]
16. Frandi A, Jacquier N, Théraulaz L, Greub G, Viollier PH 2014. FtsZ-independent septal recruitment and function of cell wall remodelling enzymes in chlamydial pathogens. Nat Commun 5:4200. doi:.10.1038/ncomms5200 [PMC free article] [PubMed] [Cross Ref]
17. Liechti GW, Kuru E, Hall E, Kalinda A, Brun YV, VanNieuwenhze M, Maurelli AT 2014. A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia trachomatis. Nature 506:507–510. doi:.10.1038/nature12892 [PMC free article] [PubMed] [Cross Ref]
18. Pilhofer M, Aistleitner K, Biboy J, Gray J, Kuru E, Hall E, Brun YV, VanNieuwenhze MS, Vollmer W, Horn M, Jensen GJ 2013. Discovery of chlamydial peptidoglycan reveals bacteria with murein sacculi but without FtsZ. Nat Commun 4:2856. doi:.10.1038/ncomms3856 [PMC free article] [PubMed] [Cross Ref]
19. Kahane S, Gonen R, Sayada C, Elion J, Friedman MG 1993. Description and partial characterization of a new Chlamydia-like microorganism. FEMS Microbiol Lett 109:329–333. doi:.10.1111/j.1574-6968.1993.tb06189.x [PubMed] [Cross Ref]
20. De Benedetti S, Bühl H, Gaballah A, Klöckner A, Otten C, Schneider T, Sahl H-G, Henrichfreise B 2014. Characterization of serine hydroxymethyltransferase GlyA as a potential source of D-alanine in Chlamydia pneumoniae. Front Cell Infect Microbiol 4:19. doi:.10.3389/fcimb.2014.00019 [PMC free article] [PubMed] [Cross Ref]
21. Kohlhoff SA, Hammerschlag MR 2015. Treatment of chlamydial infections: 2014 update. Expert Opin Pharmacother 16:205–212. doi:.10.1517/14656566.2015.999041 [PubMed] [Cross Ref]
22. Senn L, Hammerschlag MR, Greub G 2005. Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother 6:2281–2290. doi:.10.1517/14656566.6.13.2281 [PubMed] [Cross Ref]
23. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS 1995. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 39:760–762. doi:.10.1128/AAC.39.3.760 [PMC free article] [PubMed] [Cross Ref]
24. McCoy AJ, Sandlin RC, Maurelli AT 2003. In vitro and in vivo functional activity of Chlamydia MurA, a UDP-N-acetylglucosamine enolpyruvyl transferase involved in peptidoglycan synthesis and fosfomycin resistance. J Bacteriol 185:1218–1228. doi:.10.1128/JB.185.4.1218-1228.2003 [PMC free article] [PubMed] [Cross Ref]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)